Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Slides:



Advertisements
Similar presentations
Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,
Advertisements

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Heart failure and comorbidities
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Published on – 1 August, 2015 | Number of pages : 103
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program Cardiorenal Med 2011;1:45–52 - DOI: /
Copyright © 2015 by the American Osteopathic Association.
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
Diabetes and Risk of CV Outcomes
An Endocrinology Clinic in Dyslipidemia
Cardiac Troponin.
Advances in Management of Perioperative Hypotension: It Takes a Team
When Is Adding Aspirin to NOACs Worth the Risk?
Overview of Disparities
The ABCs of AF.
Hospitalizations in the United States Caused by ACS.
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Cardiac Biomarkers.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Unmet Needs in the Secondary Prevention in ACS
Introduction Antiplatelet Agents ADP Receptor Antagonists.
Select Topics in Cardiovascular Medicine
Obesity and Dyslipidemia: How Would You Treat?
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.
Heart Failure Prevention: Mission Impossible?
Panelists. Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia.
بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Are We Closer to Personalized Medicine in MS?
Part I: A Sensible Approach to Sensitive Troponin
Growing Diabetes Pandemic Worldwide
Advancing Acute Coronary Syndrome Assessment:
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.
Mitral Valve Disease.
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Using Heart Rate as a Biomarker in Clinical Practice.
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Learning Objectives Metabolic Abnormalities Associated With T2D.
Antihyperglycemic Therapy
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
Identifying High-Risk AF Patients
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
CAD/PAD in Primary Care
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
CAD and HF Often Coexist
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
Typical Patient Presentation
Antithrombotic Therapy in Vascular Protection: From CAD to HF
How to Optimize Cholesterol Management in High-Risk CV Patients
NOACs in CAD.
Elevated Admission Plasma Glucose Following ACS
Factor Xa Inhibitors in Coronary Artery Disease
The ABCs of AF.
Disease Burden of VTE Phases of VTE Treatment.
New Lipid-Lowering Guidelines
Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.
The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.
Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.
Presentation transcript:

Selected Causes of Cardiac Injury

PEACE Trial High-Sensitivity Biomarker Substudy

PEACE Trial (cont)

Dallas Heart Study

High-Sensitivity Troponin Use in Europe

Troponins and Risk Stratification in Stable Outpatient CAD

Secondary Prevention and Prognostic Value of High-Sensitivity Troponins

Diabetes Stages of Heart Failure

LURIC Study

Diabetes Prevalence Among ACS Patients

T2D and Macrovascular Disease

Incremental Risk With DM Among Patients With ACS

SAVOR-TIMI 53 Trial

Biomarker Assessments in Stable Patients With T2DM Observations From the SAVOR-TIMI 53 Trial

ADVANCE Trial

Cardiovascular Risk According to Number of Elevated Biomarkers

Biomarkers and Risk Assessment

Take-home Points

Abbreviations

References

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.